
    
      The primary objective is to determine the safety and feasibility of administering HemopureÂ®
      (HBOC-201) to reduce myocardial necrosis, as measured by CK-MB enzyme elevation, and enhance
      tissue preservation during cardiopulmonary bypass.
    
  